Browsing Tag
Disc Medicine Inc.
1 post
FDA Complete Response Letter puts Disc Medicine Inc.’s bitopertin timeline under pressure
Disc Medicine Inc. shares plunge after the FDA issues a Complete Response Letter for bitopertin. Find out what this setback means for investors and strategy.